We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+11.61%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$1.17B
AUM Growth
+$164M
Cap. Flow
+$76.2M
Cap. Flow %
6.49%
Top 10 Hldgs %
32.39%
Holding
149
New
25
Increased
54
Reduced
51
Closed
11

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$11.9M
2
CI icon
Cigna
CI
+$11.9M
3
PRAH
PRA Health Sciences, Inc.
PRAH
+$11.1M
4
VTRS icon
Viatris
VTRS
+$10.5M
5
CELG
Celgene Corp
CELG
+$8.17M

Top Sells

Rank Stock Value
1
INCY icon
Incyte
INCY
+$12M
2
UNH icon
UnitedHealth
UNH
+$11M
3
ALGN icon
Align Technology
ALGN
+$9.05M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$8.45M
5
IART icon
Integra LifeSciences
IART
+$8.23M

Sector Composition

Rank Sector Weight
1 Healthcare 93.53%
2 Industrials 0.76%
3 Technology 0.15%
4 Financials 0.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRK icon
126
Merck
MRK
$315B
$759K 0.06%
13,100
– –
VAR
127
DELISTED
Varian Medical Systems, Inc.
VAR
$716K 0.06%
6,300
-700
-10% -$83.8K
ADAP
128
DELISTED
Adaptimmune Therapeutics
ADAP
$711K 0.06%
+59,935
New +$747K
BLCM
129
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$664K 0.06%
+9,002
New +$702K
HCSG icon
130
Healthcare Services Group
HCSG
$1.74B
$648K 0.06%
15,000
-23,000
-61% -$913K
MDCO
131
DELISTED
Medicines Co
MDCO
$626K 0.05%
17,050
-550
-3% -$17.9K
CVS icon
132
CVS Health
CVS
$137B
$515K 0.04%
8,000
-800
-9% -$52.7K
MTLS
133
Materialise
MTLS
$379M
$510K 0.04%
+39,329
New +$482K
NTLA icon
134
Intellia Therapeutics
NTLA
$1.59B
$458K 0.04%
+16,734
New +$405K
MDSO
135
DELISTED
Medidata Solutions, Inc.
MDSO
$375K 0.03%
+4,649
New +$349K
AAC
136
DELISTED
AAC Holdings
AAC
$365K 0.03%
39,000
-4,700
-11% -$51.4K
VYGR icon
137
Voyager Therapeutics
VYGR
$192M
$331K 0.03%
+16,922
New +$334K
CYTO
138
DELISTED
Altamira Therapeutics Ltd
CYTO
$151K 0.01%
24
-3
-11% -$31.7K
ACAD icon
139
Acadia Pharmaceuticals
ACAD
$4.38B
– –
-34,550
Closed -$776K
EXEL icon
140
Exelixis
EXEL
$14.1B
– –
-49,800
Closed -$1.1M
GKOS icon
141
Glaukos
GKOS
$9.21B
– –
-30,000
Closed -$925K
HALO icon
142
Halozyme
HALO
$9.23B
– –
-75,800
Closed -$1.49M
MYGN icon
143
Myriad Genetics
MYGN
$584M
– –
-11,800
Closed -$349K
PRGO icon
144
Perrigo
PRGO
$1.48B
– –
-33,000
Closed -$2.75M
PRTA icon
145
Prothena Corp
PRTA
$453M
– –
-30,850
Closed -$1.13M
SGRY icon
146
Surgery Partners
SGRY
$2.09B
– –
-31,000
Closed -$532K
NUVA
147
DELISTED
NuVasive, Inc.
NUVA
– –
-32,312
Closed -$1.69M
RDUS
148
DELISTED
Radius Health, Inc.
RDUS
– –
-33,300
Closed -$1.2M
IPXL
149
DELISTED
Impax Laboratories, Inc.
IPXL
– –
-75,000
Closed -$1.46M
2 3 4 5
6

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q2 2018 Portfolio in Review

As of Q2 2018, Bellevue Group held 149 positions worth $1.17B, up 16% from $1.01B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Bellevue Group deployed $76.2M of net new capital in Q2 2018, opening 25 new positions and adding to 54 existing holdings. Its largest new stake was PRA Health Sciences, Inc.: 129,400 shares worth $12.1M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 95% a quarter earlier, followed by Industrials and Technology.

On the sell side, the largest reduction was Incyte, an estimated $12M trimmed.

  • Bellevue Group's largest Q2 2018 buy was PRA Health Sciences, Inc.: 129,400 shares worth $12.1M.
  • Bellevue Group added most to Bristol-Myers Squibb in Q2 2018, an estimated $11.9M increase.
  • Bellevue Group's biggest Q2 2018 reduction was Incyte, cutting an estimated $12M.
  • Bellevue Group fully exited Perrigo in Q2 2018, selling an estimated $2.75M.
  • Bellevue Group's ten largest holdings make up 32% of its $1.17B portfolio in Q2 2018.
  • Bellevue Group opened 25 new positions and closed 11 in Q2 2018.
  • Bellevue Group's portfolio value rose 16% quarter-over-quarter to $1.17B.

Based on Bellevue Group's 13F filing for Q2 2018, filed 7 Aug 2018.